Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

Chronic Hepatitis D Infection Clinical Trial

Official title:

A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05765344
• Other study ID #: GS-US-589-6162
• Status: Recruiting
• Phase: Phase 1
• Start date: March 15, 2023
• Est. completion date: February 2025

Study information

• Verified date: May 2024
• Source: Gilead Sciences
• Contact: Gilead Clinical Study Information Center
• Phone: 1-833-445-3230 (GILEAD-0)
• Email: GileadClinicalTrials[@]gilead.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Key Inclusion Criteria:

All individuals:

• Body mass index (BMI) of at least 19 and no greater than 40 kg/m^2 at screening.
• Have a calculated creatinine clearance (CLcr) of at least 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening.
• Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in the protocol.
• Individuals have not donated blood within 56 days of study entry or plasma within 7 days of study entry and must refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study drug.
• 12-lead electrocardiogram (ECG) evaluations at screening must be without clinically significant abnormalities as assessed by the investigator.
• Aside from hepatic impairment among the individuals with hepatic impairment, the individual must, in the opinion of the investigator, be sufficiently healthy for study participation based upon medical history, physical examination, vital signs, and screening laboratory evaluations.
• Must be willing and able to comply with all study requirements.

Individuals With Hepatic Impairment:

• Have a diagnosis of chronic (> 6 months), stable hepatic impairment (moderate or severe based upon the Child-Pugh-Turcotte (CPT) classification system for moderate or severe hepatic impairment [CPT Class B or C, respectively]) with no clinically significant change in hepatic status (as determined by the investigator) within the 2 months (60 days) prior to screening.
• Individuals with moderate or severe hepatic impairment must have a score of 7 to 9 or 10 to 15 on the CPT classification system at screening. If an individual's score changes during the study, the score at screening will be used for classification.
• Must meet all of the following laboratory parameters at screening:
• alanine aminotransferase (ALT) = 10 × upper limit of normal (ULN)
• aspartate aminotransferase (AST) = 10 × ULN
• platelets = 25,000/mm^3
• hemoglobin = 9 g/dL
• Individuals with hepatic impairment who have not been on a stable dose of concomitant medications for at least 4 weeks prior to screening (or 5 half-lives, whichever is longer) and/or for whom dose changes are likely to occur during the study should have their medications reviewed and approved by the sponsor.

Matched Control Individuals With Normal Hepatic Function:

• Have alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, a-fetoprotein, international normalized ratio, and total bilirubin at or below the ULN; and albumin above the lower limit of normal at screening and at admission.
• Must be matched for age (± 10 years), sex (assigned at birth), and BMI (± 20%, 19 = BMI = 40 kg/m^2) with a individual in the hepatic impairment group. Key Exclusion Criteria:

All Individuals:

• Positive serum pregnancy test at screening and at admission.
• Breastfeeding individual.
• Have received any study drug within 30 days prior to study dosing.
• Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual compliance or individual safety, or a positive drug or alcohol test at screening or admission.
• Have poor venous access that limits phlebotomy.
• Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study.
• Have a history of any of the following:
• Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria.
• Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity).
• Known hypersensitivity to the study drugs, their metabolites, or to formulation excipients.
• Significant cardiac disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, or dilated cardiomyopathy with left ventricular ejection fraction = 40%); or a family history of long QT syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years.
• Syncope, palpitations, or unexplained dizziness.
• Implanted defibrillator or pacemaker.
• Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions requiring prolonged (= 6 months) medical treatment.
• Have any serious or active medical or psychiatric illness (including depression).
• Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.

Individuals With Hepatic Impairment:

• Have a positive test result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody with detectable HCV ribonucleic acid (RNA) at screening.
• Suspicion of hepatocellular carcinoma (ie, if alpha-fetoprotein > 20 ng/mL at screening).
• Anticipated changes in concomitant medications or dosage used to treat symptoms of hepatic impairment or associated comorbid conditions that could lead to clinically significant changes in medical conditions during the study.
• Use of known hepatotoxic medications, clinical organic anion transporting polypeptide (OATP)1B1/3 inhibitors, or sodium-taurocholate cotransporting polypeptide (NTCP) inhibitors (half-maximal inhibitory concentration (IC50) or kinetic inhibition constant [Ki] < 20 µM).
• Positive test for drugs of abuse, including alcohol at screening or admission, with the exception of opioids and tetrahydrocannabinol (marijuana) under prescription and verified by the investigator as for pain management.

Matched Control Individuals With Normal Hepatic Function:

• Have a positive test result for HIV antibody, HBsAg, or HCV antibody.
• Have a history of liver disease including Gilbert's disease.
• Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medications. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Chronic Hepatitis D Infection
• Hepatitis D
• Hepatitis D, Chronic

Intervention

Drug:
• Bulevirtide
Administered via subcutaneous injections.

Locations

Country	Name	City	State
United States	Orange County Research Center	Lake Forest	California
United States	Clinical Pharmacology of Miami, LLC	Miami	Florida
United States	University of Miami	Miami	Florida
United States	Orlando Clinical Research Center	Orlando	Florida
United States	Pinnacle Clinical Research LLC	San Antonio	Texas
United States	Texas Liver Institute	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)	AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state.	Day 6: Predose and up to 24 hours postdose
Primary	PK Parameter: Cmax,ss of BLV	Cmax,ss is defined as the maximum observed concentration of drug at steady state.	Day 6: Predose and up to 24 hours postdose
Secondary	PK Parameter: AUC0-24h of BLV	AUC0-24h is defined as the partial area under the concentration versus time curve from time zero to time 24 hours.	Day 1: Predose and up to 24 hours postdose
Secondary	PK Parameter: Tmax of BLV	Tmax is defined as the time (observed time point) of Cmax.	Days 1 and 6: Predose and up to 24 hours postdose
Secondary	PK Parameter: Cmax of BLV	Cmax is defined as the maximum observed concentration of drug.	Day 1: Predose and up to 24 hours postdose
Secondary	PK Parameter: t1/2 of BLV	t1/2 is defined as the terminal elimination half-life.	Day 1: Predose and up to 24 hours postdose; Day 6: Predose and up to 48 hours postdose
Secondary	PK Parameter: CLss/F of BLV	CLss/F is defined as the apparent oral clearance at steady state.	Day 6: Predose and up to 48 hours postdose
Secondary	PK Parameter: Vss/Fv of BLV	Vss/F is defined as the apparent steady-state volume of distribution of the drug.	Day 6: Predose and up to 48 hours postdose
Secondary	PK Parameter: Ctrough of Total Bile Acid (BA)	Ctrough is defined as the concentration of total BA at the end of the dosing interval.	Day 2 up to Day 5 (predose), Day 7, and Day 8
Secondary	PK Parameter: Cmax of Total BA	Cmax is defined as the maximum observed concentration of total BA.	Days 1 and 6: Predose and up to 24 hours postdose
Secondary	PK Parameter: AUC0-24h of Total BA	AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours.	Days 1 and 6: Predose and up to 24 hours postdose
Secondary	PK Parameter: Tmax of Total BA	Tmax is defined as the time (observed time point) of Cmax of total BA.	Days 1 and 6: Predose and up to 24 hours postdose
Secondary	Percentage of Participants with Treatment-emergent Adverse Events		First dose date up to 6 days plus 7 days
Secondary	Percentage of Participants with Laboratory Abnormalities		First dose date up to 6 days plus 7 days

External Links

•   Gilead Clinical Trials Website